Coagulation factor XIII in scleroderma

European Journal of Dermatology

Volumn 8, Issue 4, 1998, Pages 231-234

  Jullien, Denis ^a,b   Souillet, Anne Laure ^a   Faure, Michel ^a   Claudy, Alain ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Coagulation factor XIII; Scleroderma; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; COLLAGEN; FIBROGAMMIN P; FIBRONECTIN; UNCLASSIFIED DRUG;

ARTHRALGIA; BLOOD CLOTTING; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DYSPHAGIA; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; PATHOPHYSIOLOGY; QUALITY OF LIFE; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA;

EID: 0031845990     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Soria J, Soria C, Boulard C. Proceedings: Action of factor XIII on transamidation bonds between the collagen molecule constituents. Thromb Diath Haemorrh 1975; 34: 551.
2. Thivolet J, Perrot H, Meunier F, Bouchet B. Therapeutic action of coagulation factor XIII in scleroderma. 20 cases. Nouv Presse Med 1975; 4: 2779-82.
3. Paye M, Read D, Nusgens B, Lapiere CM. Factor XIII in scleroderma: in vitro studies. Br J Dermatol 1990; 122: 371-82.
4. Mosher DF, Schad PE. Cross-linking of fibronectin to collagen by blood coagulation factor XIIIa. J Clin Invest 1979; 64: 781-7.
5. Guillevin L, Chouvet B, Mery C, Thivolet J, Godeau P, Delbarre F. Treatment of generalized scleroderma with factor XIII. Study of 25 cases. Rev Med Interne 1982; 3: 273-7.
6. Vitto J, Ohlenschlager K, Lorenzer I. Solubility of skin collagen in normal human subjects and in patients with generalized scleroderma. Clin Chim Acta 1971; 31: 13-8.
7. Barry EL, Mosher DF. Binding and degradation of blood coagulation factor XIII by cultured fibroblasts. J Biol Chem 1990; 265: 9302-7.
8. Paye M, Nusgens BV, Lapiere CM. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro. Haemostasia 1989; 19: 274-83.
9. Paye M, Nusgens B, Lapiere CM. Factor XIII of blood coagulation decreases the susceptibility of collagen precursors to proteolysis. Biochim Biophys Acta 1991; 1073: 437-41.
10. Ueyama M, Urayama T. The role of factor XIII in fibroblast proliferation. Jpn J Exp Med 1978; 48: 135-42.
11. Winkelman L, Sims GE, Haddon ME, Evans DR, Smith JK. A pasteurised concentrate of human plasma factor XIII for therapeutic use. Thromb Haemost 1986; 55: 402-5.
12. Burnouf-Radosevich M, Burnouf T, Huart JJ. Industrial pasteurization of plasma and criteria of quality. Rev Fr Transfus Hemobiol 1993; 36: 93-102.
13. Lai TS, Santiago MA, Achyuthan KE, Greenberg CS. Purification and characterization or recombinant human coagulant factor XIII A-chains expressed in E. coli. Protein Expr Purif 1994; 5: 125-32.
14. Guillevin L, Euller-Ziegler L, Chouvet B, De Gery A, Chassoux G, Lafay P, Ziegler G, Godeau P, Amor B, Thivolet J. Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up. Presse Med 1985; 14: 2327-9.
15. Euller-Ziegler L, Corolleur YR, Marcou J, Commandre F, Grisot C, Ziegler G. Long-term treatment of systemic scleroderma with coagulation factor XIII. Developmental monitoring, especially of respiratory function. Rev Rhum Mal Osteoartic 1984; 51: 503-5.
16. Maekawa Y, Nogita T, Yamada M. Favorable effects of plasma factor XIII on lower esophageal sphincter pressure of progressive systemic sclerosis. Arch Dermatol 1987; 123: 1440-1.
17. Marzano A, Gasparini G, Colonna C, Berti E, Caputo R. Treatment of systemic scleroderma and generalized morphoea with coagulation factor XIII. Eur J Dermatol 1995; 5: 459-66.
18. Delbarre F, Godeau P, Thivolet J. Factor XIII treatment for scleroderma. Lancet 1981; 2: 204.
19. Brackmann HH, Egbring R, Ferster A, Fondu P, Girardel JM, Kreuz W, Masure R, Miloszewski K, Stibbe J, Zimmermann R, et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
20. Gulllevin L, Chouvet B, Mery C, De Gery A, Thivolet J, Godeau P, Delbarre F. Treatment of progressive systemic sclerosis using factor XIII. Pharmatherapeutica 1985; 4: 76-80.
21. Grivaux M, Pieron R. Bronchiole-alveolar carcinoma complicating systemic scleroderma under long-term treatment with factor XIII. Rev Pneumol Clin 1987; 43: 102-3.